

Index to Volume Nineteen

Index of Issues: January–February 1–60: March–April 61–122: May–June 123–184: July–August 185–242: September–October 243–302: November–December 303–364.

INDEX OF AUTHORS

- A**
- Albritton WL, 279
 Alexander WJ, 14
 Alfa MJ, 309
 Almaraz A, 39
 Anderson J, 326
 Anderson JE, 320
 Andersson B, 140
 Aral S, 331
 Athey TW, 230
 Austin H, 14
- B**
- Baddour LM, 341
 Barrett CL, 14
 Beebe JL, 47
 Beller M, 41
 Bernal M, 291
 Bharucha H, 225
 Bianchi A, 161
 Bobo L, 303
 Bolan GA, 7
 Bollrup AC, 206
 Bratos MA, 39
 Busby L, 341
- C**
- Caine VA, 99, 351
 Carballo M, 219
 Carey RF, 230
 Carlson RG, 266
 Caro-Patón A, 39
 Carter RJ, 272
 Celentano DD, 175
 Chan C-BB, 284
 Chang S-J, 335
 Cheng SF, 193
 Chernesky MA, 243, 315
 Clay JC, 298
 Cohen DA, 245
 Conidou G, 78
 Conlon R, 346
 Cox KB, 341
 Csángó PA, 133, 149
- D**
- Dahlberg LL, 320
 Daling JR, 28
 Dallabetta G, 88
 Daniel RW, 203
- Davies AG, 298
 Deboer M, 326
 Degagne P, 309
 Dent C, 245
 Desenclos J-CA, 105
 Dillon J-AR, 219
 Dinsmore WW, 181, 225
 Dunnett DM, 92
- E**
- Egglesstone S, 284
 Eiros JM, 39
 Embil JA, 115
- F**
- Faden RR, 326
 Falck R, 266
 Farris KB, 272
 Felten A, 161
 Flaherty EE, 259
 Foreman P, 213
 Forney MA, 266
 Foxman B, 272
 Fullilove M, 7
 Fullilove R, 7
- G**
- Garritty D, 105
 Gaydos CA, 303
 Gellin B, 41
 Gielen AC, 326
 Glassco S, 341
 Gnarp H, 84
 Gonzalez JM, 39
 Gorter RG, 111
 Greenberg J, 331, 346
 Gutierrez P, 39
 Guzmán J, 291
 Guzmán M, 291
- H**
- Haase DA, 115
 Hadler SC, 14
 Hagdu A, 185
 Hahn G, 245
 Haivanis RM, 259
 Hallén A, 146
 Hamed KA, 339
 Handley JM, 181, 225
- Hart G, 181
 Hellberg D, 170
 Heller-Vitouch C, 252
 Henneberry JF, 47
 Herman BA, 230
 Herman WA, 230
 Hermonat PL, 203
 Hill HE, 288
 Hillier SL, 198
 Hofmann H, 252
 Holmes KK, 54
 Hook EW III, 88, 175, 213, 243, 303
 Horner T, 225
 Humphreys JT, 47
- I**
- Ingle D, 41
- J**
- Jagers G, 149
 Jang D, 315
 Jarstrand C, 146
 Jensen IP, 165
 Jetsawangsi T, 295
 Joesoef R, 185
 Joffe GP, 272
 Johnson JK, 341
 Jones RB, 99, 243, 351
 Jones WE, 259
 Judson FN, 243
 Juntunen L, 140
- K**
- Kam K-M, 284
 Kass N, 326
 Kataja V, 154
 Katz BP, 99, 351
 Keffelew AS, 111
 Kellogg JA, 243
 Kennedy CA, 288
 Kiviat NB, 54
 Knapp JS, 35
 Knud-Hansen CR, 88
 Kohn R, 7
 Kopp W, 252
 Ko Y-C, 335
 Kreiss JK, 54
 Krohn K, 127
 Kubicek M, 121
 Kunz C, 252
- L**
- Lai C-F, 284
 Lassus J, 127
 Lawther H, 225
 LeBar B, 243
 Lee M-F, 193
 Li L, 266
 Lind I, 206
 Lin J-SL, 259
 Louv WC, 14
 Lutz B, 94
 Luz-Jimenez M, 28
- M**
- MacKinnon D, 245
 Magder L, 331
 Mahony JB, 315
 Malyk B, 25
 Manley KM, 115
 Mäntytjärvi R, 137, 154
 Mårdh P-A, 243
 Maw RD, 225
 McCann DF, 288
 McCormack WM, 243
 McCray E, 235
 McCright J, 7
 McKnight B, 28
 Mentis A, 78
 Meouchy R, 161
 Middaugh J, 41
 Miller H, 121
 Miller JN, 355
 Mogabgab WJ, 94
 Montalvo M, 94
 Moore DE, 28
 Morel P, 161
 Moss AR, 111
 Moyer MA, 92
 Mueller BA, 28
 Mumford DM, 19
- N**
- Namaara W, 309
 Neumann S, 272
 Neumann T, 213
 Ngugi E, 54
 Niemi K-M, 127
 Nilsen A, 149
 Nugent RP, 198

O

O'Campo P, 326
 Odland V, 84
 Oldfield EC III, 288
 Olson N, 309
 Onorato IM, 235
 O-Prasertsawat P, 295
 Orduña A, 39

P

Paavonen J, 123
 Pabst KM, 88
 Pålsson C, 146
 Pedersen BS, 149
 Pereira LH, 115
 Perol Y, 161
 Pickard L, 315
 Plummer F, 54, 309
 Portilla I, 94
 Psarrou E, 78

Q

Quinn TC, 88, 175, 243, 303

R

Rahm V-A, 84
 Ranki A, 127

Ray P, 175
 Reichart CA, 88, 175, 213
 Reimann K, 206
 Retta SM, 230
 Reynolds G, 185
 Rice PA, 259
 Rickard RS, 47
 Ridgway GL, 243
 Rinaldi JE, 230
 Roberts PL, 54
 Rodríguez-Torres A, 39
 Rolfs RT, 7
 Ronald AR, 309, 356

S

Saarikoski S, 137, 154
 Salman J, 1
 Sarafian SK, 35
 Scaggs M, 105
 Schachter J, 123, 243
 Schiøtz HA, 133
 Schmidt AJ, 272
 Schnell D, 346
 Schwarz SK, 7
 Scieux C, 161
 Sellors JW, 315
 Sell S, 1
 Shah KV, 88, 203

Shapiro E, 341
 Siegal HA, 266
 Skuland J, 149
 Slaney L, 309
 Smith PB, 19
 Spence MR, 25
 Spiliopoulou D, 78
 Stamm WE, 243
 Stary A, 252
 Stellato G, 124
 Studemeister AE, 339
 Syrjänen K, 137, 140, 154
 Syrjänen S, 127, 140, 154

T

Taylor-Robinson D, 243
 Tervahauta A, 137
 Thompson SE, 185
 Tolo K-A, 272
 Tsoumaris L, 78

U

Upchurch DM, 175

V

Vassias I, 161
 Viscidi R, 303

von Krogh G, 170
 Vranizan KM, 111
 Vretou E, 78

W

Waiyaki P, 54
 Walters AM, 272
 Wang J, 266
 Wasserheit JN, 61, 88
 Weinman M, 19
 Weiss NS, 28
 Weiss PJ, 288
 Welsh L, 303
 Westrom L, 185
 Wirthwein KA, 259
 Wolfe H, 111
 Wroten JE, 105
 Wu C-H, 193

Y

Yang D-M, 193
 Yan L, 259
 Yin S-C, 193
 Yliskoski M, 137, 154

Z

Zenilman JM, 213
 Zwickl BW, 351

INDEX OF SUBJECTS

A

Abortion applicants, human papillomavirus infection in, 149
 Acquired immunodeficiency syndrome. *See also* Human immunodeficiency virus infection
 in homosexuals, in Taiwan, 335
 knowledge, beliefs, and risk factors for, in inner city adolescent girls, 19
 Adolescents, inner city
 exchange of sex for crack cocaine by, 7
 knowledge, beliefs, and risk factors for HIV infection in, 19
 Adsorption enzyme immunoassay, for *H. ducreyi*, 309
 Age, at first coitus, as high-risk sexual behavior marker, 331
 Alpha 2B interferon, intralesional, for human papillomavirus-associated cervical intraepithelial neoplasia, 124
 American Social Health Association (ASHA)
 public affairs activities of, 183
 status report for, 301
 Ampicillin/sulbactam with probenecid, vs. ceftriaxone, for gonorrhea, 341
 Anogenital warts. *See* Condylomata acuminata
 Antibiotic resistance, of *Neisseria gonorrhoeae*, temporal trends in, 213
 Antibiotic susceptibility, of *Neisseria gonorrhoeae*, in Hong Kong (1987-1990), 284
 Antibiotic therapy. *See also* specific drugs
 for chlamydia and gonorrhea, compliance with, 351
 Antigen detection tests, for *C. trachomatis*, 315, 161, 243, 259
 Anti-hepatitis C virus antibodies, in FTA-ABS—positive, non-drug abusing prostitutes, 39

ASHA. *See* American Social Health Association (ASHA)
 Axons, cutaneous nerve, *Treponema pallidum* in, 1

B

Bacterial endocarditis, penicillinase-producing *N. gonorrhoeae* and, 288
 Bacterial vaginosis, lactobacilli for, 146
 Barrier methods. *See also* Condoms
 use of, after STD episode, 326
 Biotinylated human papillomavirus DNA probes, for in situ hybridization, polymerase chain reaction for production of, 140

C

Cefixime, for uncomplicated gonorrhea, 92
 vs. intramuscular ceftriaxone, 92
 Ceftriaxone
 intramuscular, vs. oral cefixime, for gonorrhea, 94
 vs. ampicillin/sulbactam with probenecid, for gonorrhea, 341
 Cervical infections, effect of on human papillomavirus-associated cervical lesions, 137
 Cervical intraepithelial neoplasia, human papillomavirus-associated HPV DNA detection in, by in situ hybridization, 225
 intralesional alpha 2B interferon for, 124
 in Kenyan prostitutes, 54
 Cervicitis, mucopurulent, in prediction of chlamydial infection and adverse pregnancy outcome, 198
 Cervix, human papillomavirus infection of. *See* Human papillomavirus infection

- Chancroid**
 adsorption enzyme immunoassay for, 309
 HIV infection and, 61
 molecular epidemiology of, 35
 single-dose spectinomycin for, 291
- Chemiluminometric immunoassay (Magic Lite Chlamydia), for *C. trachomatis* antigen, 315, 161**
- Chlamydia trachomatis***
 rare serovar Da of, in Greece, 78
 gene typing of, by polymerase chain reaction and restriction endonuclease digestion, 303
- Chlamydia trachomatis* infection**
 antibiotic therapy for, compliance with, 351
 diagnosis of
 by chemiluminometric immunoassay (Magic Lite Chlamydia), 315, 161
 by polymerase chain reaction, monoclonal antibody-based enzyme immunoassay, and cell culture, 193
 urine sample vs. urethral swab for, 165
 field follow-up for, 99
 HIV infection and, 61
 multiple partners and partner choice as risk factors for, in female college students, 272
 nonculture tests for, 243, 259
 prevalence of, among women attending STD clinic, 88
 screening for
 by direct fluorescence assay, 84
 in pregnancy, mucopurulent cervicitis and, 198
 selective, cost-benefit analysis for, 47
 test-of-cure consultation for, cost-benefit analysis for, 133
 underdiagnosis of, 259
- Clinic service, addition of evening hours to, patient attendance and (letter), 181**
- Coagglutination assay, for monoclonal antibody typing of *N. gonorrhoeae*, 219**
- Cocaine. See Crack cocaine**
- Coitus, age at first, as high-risk sexual behavior marker, 331**
- Condoms**
 latex, barrier effectiveness of, for HIV-sized virus particles, 230
 use of
 after STD episode, 326
 brief promotion programs for, 245
 prevalence and patterns of, among STD clinic patients, 175
- Condylomata acuminata**
 anogenital, topical tretinoin for (letter), 181
 human papillomavirus DNA detection in, by in situ hybridization, 225
 penile, diagnosis of, histopathologic vs. demonstration of HPV-specific DNA and proteins, 127
 self-treatment of, with podophyllotoxin cream, 170
- Contact tracing, for gonorrhea and *C. trachomatis* infection, 99**
- Crack cocaine use**
 exchange of sex for money or drugs with, gonorrhea and, 7
 high-risk behavior with
 for gonorrhea, 7
 for HIV infection, 111, 266
 for syphilis, 346, 266
 with IV drug use, HIV infection and, 111
- Cutaneous nerve axons, *Treponema pallidum* in, 1**
- D**
- Da serovar, of *C. trachomatis*, in Greece, 78**
- Diagnostics. See also Screening and specific techniques**
 population-based, in STD laboratory, 279
- Direct fluorescence assay, for *C. trachomatis* screening, 84**
- Direct immunofluorescence tests, for *C. trachomatis*, 243, 259**
- DNA, human papillomavirus-specific**
 detection of, by in situ hybridization, 225
 in diagnosis of penile warts, 127
- DNA probes, biotinylated human papillomavirus, polymerase chain reaction for production of, 140**
- Drug abuse. See Crack cocaine**
- E**
- Endocarditis, fulminant, penicillinase-producing *N. gonorrhoeae* and, 288**
- Enzyme immunoassay**
 for *H. ducreyi*, IX
 for monoclonal antibody typing of *N. gonorrhoeae*, 219
 vs. polymerase chain reaction and cell culture, for *C. trachomatis* detection, 193
- Enzyme-linked immunosorbent assay, for *C. trachomatis*, 243, 259**
- F**
- Fertility, pelvic inflammatory disease and, 28, 185**
- Field follow-up, for gonorrhea and *C. trachomatis* infection, 99**
- Fitzgerald, Thomas James (obituary), 355**
- G**
- Genital ulcer disease, HIV infection and, 61**
- Gonococcal infection. See also Gonorrhea; *Neisseria gonorrhoeae***
 endocardial, 288
 neonatal, in Florida, 105
- Gonococcal ophthalmia neonatorum, in Florida, 105**
- Gonococci. See *Neisseria gonorrhoeae***
- Gonorrhea. See also Gonococcal infection; *Neisseria gonorrhoeae***
 antibiotic therapy for, compliance with, 351
 cefixime for, 92
 vs. intramuscular ceftriaxone, 92
 and exchange of sex for crack cocaine, 7
 field follow-up for, 99
 HIV infection and, 61, 115
 incidence rates for, reinfection and, 41
 prevalence of, among women attending STD clinic, 88
 single-dose ampicillin/sulbactam with probenecid vs. ceftriaxone for, 341
- Greece, rare serovar Da of *C. trachomatis* in, 78**
- H**
- Haemophilus ducreyi* infection. See Chancroid**
- Hepatitis B virus infection, risk factors for, in women, 14**
- Hepatitis C virus, antibodies to, in FTA-ABS—positive, non-drug abusing prostitutes, 39**
- Hepatitis C virus infection, sexual transmission of, seroepidemiologic study of, 252**
- Herpes simplex virus infection, HIV infection and, 61**
- Homosexuals, sexual patterns and HIV infection in, in Taiwan, 335**
- Hong Kong, *Neisseria gonorrhoeae* antibiotic susceptibility in, 284**
- Human immunodeficiency virus, latex condom barrier effectiveness against, 230**
- Human immunodeficiency virus infection. See also Acquired immune deficiency syndrome**
 cervical intraepithelial neoplasia and, in Kenyan prostitutes, 54
 in crack users
 high-risk behavior for, 266
 with IV drug abuse, 111

- in homosexuals, in Taiwan, 335
- knowledge, beliefs, and risk factors for, in inner city adolescent girls, 19
- new-onset peripartum seizures and, 25
- sentinel surveillance of, 235
- sexually transmitted diseases and, epidemiologic synergy among, 61, 115
- in STD clinic patients, 115
- Human papillomavirus, nonoxynol-9 inactivation of, 203
- Human papillomavirus-associated cervical intraepithelial neoplasia
 - HPV DNA detection in, by in situ hybridization, 225
 - intralesional alpha 2B interferon for, 124
 - in Kenyan prostitutes, 54
- Human papillomavirus DNA detection, by in situ hybridization, in anogenital warts and cervical intraepithelial neoplasia, 225
- Human papillomavirus infection
 - in abortion applicants and STD clinic patients, 149
 - HIV infection and, 61
 - lesions in, effect of coexistent cervical infections on, 137
 - multiple partners and partner choice as risk factors for, in female college students, 272
 - prognostic factors in, 154
- Human papillomavirus-specific DNA and proteins, in diagnosis of penile warts, 127

I

- Infertility, pelvic inflammatory disease and, 28, 185
- In situ hybridization, for human papillomavirus DNA detection, in anogenital warts and cervical intraepithelial neoplasia, 225
- Intercourse, age at first, as high-risk sexual behavior marker, 331
- Interferon, intralesional, for human papillomavirus-associated cervical intraepithelial neoplasia, 124

K

- Kenyan prostitutes, HIV, human papillomavirus, and cervical intraepithelial neoplasia in, 54

L

- Lactobacilli, for bacterial vaginosis, 146

M

- Magic Lite Chlamydia, for *C. trachomatis* antigen detection, 315, 161
- Metronidazole, split-dose, for vaginal trichomoniasis, vs. single-dose tinidazole, 295
- Modified coagglutination assay, for monoclonal antibody typing of *N. gonorrhoeae*, 219
- Monoclonal antibodies, in typing of *N. gonorrhoeae* isolates, 219
- Monoclonal antibody-based enzyme immunoassay, vs. polymerase chain reaction and cell culture, for *C. trachomatis* detection, 193

N

- National Institutes of Health grants, for STD cooperative research centers, 121
- Neisseria gonorrhoeae*. See also Gonorrhea
 - antibiotic resistance of, temporal trends in, 213
 - antibiotic susceptibility of, in Hong Kong (1987-1990), 284
 - monoclonal antibody typing of, by enzyme immunoassay and modified coagglutination assay, 219
 - non-penicillinase-producing, novel large plasmid in, 207

- penicillinase-producing
 - carrying 4.9 kb (Toronto) plasmid, 207
 - fulminant endocarditis and, 288
- Nerves, cutaneous, *Treponema pallidum* in axons of, 1
- Newborns, gonococcal infection in, in Florida, 105
- Nonoxynol-9, human papillomavirus inactivation by, 203

O

- Ophthalmia neonatorum, gonococcal, 015

P

- Papillomavirus infection. See Human papillomavirus infection
- Parran Award, remarks upon acceptance of, by Allan R. Ronald, 356
- Pelvic inflammatory disease
 - fertility and, 28, 185
 - HIV infection and, 61
- Penile warts, diagnosis of, histopathologic vs. demonstration of HPV-specific DNA and proteins, 127
- Peripartum seizures, new-onset, HIV infection and, 25
- Podophyllotoxin cream, for self-treatment of condylomata acuminata, 170
- Polymerase chain reaction
 - for producing biotinylated human papillomavirus DNA probes for in situ hybridization, 140
 - vs. monoclonal antibody-based enzyme immunoassay and cell culture, for *C. trachomatis* detection, 193
 - for gene typing of *C. trachomatis*, with restriction endonuclease digestion, 303
- Population-based diagnostics, 279
- Pregnancy
 - chlamydial infection in, mucopurulent cervicitis in screening for, 198
 - peripartum seizures in, new-onset, HIV infection and, 25
- Prostitutes
 - cervical intraepithelial neoplasia in, HIV and human papillomavirus and, in Nairobi, Kenya, 54
 - crack cocaine-using, high-risk behavior in
 - for gonorrhea, 7
 - for HIV, 266
 - for syphilis, 346, 266
 - FTA-ABS—positive, non-drug abusing, anti-hepatitis C virus antibodies in, 39

R

- Rape victims, sexually transmitted diseases in, 298
- Restriction endonuclease digestion, for gene typing of *C. trachomatis*, with polymerase chain reaction, 303
- Ronald, Allan R., Parran Award winner, 356

S

- Safe sex practices, in patients with prior STD, 326
- Scandinavian Society for Genitourinary Medicine 1990 meeting, papers from, 123-154
- Screening, for *C. trachomatis* infection
 - cost-benefit analysis for, 47
 - by direct fluorescence assay, 84
 - in pregnancy, mucopurulent cervicitis and, 198
- Seizures, new-onset, in peripartum period, HIV infection and, 25

- Sexual behavior, high-risk
 and age at first coitus, 331
 in crack cocaine users, 7, 111, 266
 in female college students, 272
 in general population, 320
 reduction of, after STD episode, 326
- Sexually transmitted disease clinic, patient attendance at, with addition of evening hours (letter), 181
- Sexually transmitted disease cooperative research centers, NIH grants for, 121
- Sexually transmitted disease laboratory, population-based diagnostics and, 279
- Sexually transmitted diseases. *See also* specific diseases
 and HIV infection, epidemiologic synergy among, 61
 multiple partners and partner choice as risk factors for, in female college students, 272
 prevalence of, among women attending STD clinic, 88
 prior episode of, and subsequent sexual risk-reduction practices, 326
 in women alleging rape, 298
- Spectinomycin, single-dose, for chancroid, 291
- Spermicide nonoxynol-9, human papillomavirus inactivation by, 203
- Substance abuse. *See* Crack cocaine use
- Syphilis
 high-risk behavior for, in crack cocaine users, 266
 HIV infection and, 61, 115
- T
- Test-of-cure consultation, for *C. trachomatis* infection, cost-benefit analysis for, 133
- Tinidazole
 for metronidazole-resistant trichomoniasis, 339
 single-dose, for vaginal trichomoniasis, vs. split-dose metronidazole, 295
- Toronto (4.9 kb) plasmid, in penicillinase-producing *N. gonorrhoeae*, 207
- Treatment compliance, in gonorrhea, 351
- Treponemal antibodies, anti-hepatitis C virus antibodies and, in non-drug abusing prostitutes, 39
- Treponema pallidum*, in axons of cutaneous nerves, 1
- Tretinoin, topical, for anogenital warts, 181
- Trichomoniasis
 HIV infection and, 61
 metronidazole-resistant, tinidazole for, 339
 prevalence of, among women attending STD clinic, 88
 split-dose metronidazole vs. single-dose tinidazole for, 295
- Tubal infertility, pelvic inflammatory disease and, 28, 185
- U
- Ulcers, genital, HIV infection and, 61
- Urethral swab, vs. urine sample, for *C. trachomatis* detection, 315, 165
- Urethritis, gonococcal. *See* Gonorrhea
- Urine sample, vs. urethral swab, for *C. trachomatis* detection, 315, 165
- V
- Vaginitis, trichomonal. *See* Trichomoniasis
- Vaginosis, bacterial, lactobacilli for, 146
- Viral particles, latex condom barrier effectiveness against, 230
- W
- Warts. *See* Condylomata acuminata